Comparison of mouse models reveals a molecular distinction between psychotic illness in PWS and schizophrenia (2021)
Attributed to:
De-risking PWS drug development through preclinical screening
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/2021.01.26.428232
Publication URI: http://dx.doi.org/10.1101/2021.01.26.428232
Type: Preprint